2 completed, 2 not yet recruiting, 1 recruiting. 5 Phase 1.
By phase and status
Follow INCB161734: new trials by email Literature Review of INCB161734 trials Research Report on INCB161734
Trials (filtered) newest first · largest first
All 5 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis
INCB161734 - Renal Insufficiency, Kidney Diseases | Phase 1 | Not yet recruiting | 24 | 2026-10-26 | 2026-10-02 |
A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment
INCB161734 - Hepatic Insufficiency, Liver Diseases | Phase 1 | Not yet recruiting | 24 | 2026-10-13 | 2026-10-01 |
A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male Participants
INCB161734 - Healthy Participants | Phase 1 | Completed | 10 | 2026-09-18 | 2026-11-06 |
A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants
INCB161734, Itraconazole, Rifampin - Healthy Participants | Phase 1 | Completed | 63 | 2025-07-16 | 2025-11-26 |
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
INCB161734, Cetuximab, Retifanlimab - Solid Tumors | Phase 1 | Recruiting | 710 | 2024-01-04 | 2026-07-22 |
Conditions studied
Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Hepatic Insufficiency (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Liver Diseases (1) · Lymphoma, Follicular (1) · Renal Insufficiency (1)
Sponsors
Incyte Corporation (5)
Countries
United States (3) · Australia (1) · Belgium (1) · Canada (1) · France (1) · Italy (1) · Japan (1) · Spain (1)
NIH funding
2023 (1)